JD.Com Inc vs Medpace Holdings Inc — how do they compare? JD.Com Inc trades at $31.46 (market cap $44.04B), while Medpace Holdings Inc trades at $607 (market cap $16.90B). The key difference: JD.Com Inc is far larger — about 2.6× Medpace Holdings Inc's market cap, and JD.Com Inc pays a 3.13% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| JD | MEDP | |
|---|---|---|
Market Cap | $44.04B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $36.17 | $620.59 |
52-Week Low | $25.19 | $393.42 |
Enterprise Value | $30.10B | $16.52B |
Dividend Yield | 3.13% | — |
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.
JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →